论文部分内容阅读
目的比较两种基于硼替佐米治疗难治性或复发性多发性骨髓瘤(MM)的方案临床疗效及不良反应,即硼替佐米联合环磷酰胺和地塞米松组(A组),以及硼替佐米联合环磷酰胺、地塞米松和沙利度胺组(B组)。方法 32例患者接受至少2个周期的A化疗方案;30例患者接受至少2个周期的B方案,即在A方案基础上联合使用沙利度胺。结果 A组和B组的治疗有效率分别为84.4%和86.7%(P>0.05)。两组血液学毒性不良反应发生率相似。在非血液学毒性不良反应,B组较A组具有较高的恶心、便秘、运动神经病变、感觉神经病变和头晕发生率(P<0.05)。结论 A方案与B方案相比在治疗复发性或难治性MM具有相似的治疗效果且具有较低的严重性非血液学毒性。
Objectives To compare the clinical efficacy and side effects of two bortezomib-based regimens for the treatment of refractory or relapsed multiple myeloma (MM), namely, bortezomib in combination with cyclophosphamide and dexamethasone (group A) and boron Temazolom combined with cyclophosphamide, dexamethasone and thalidomide (group B). Methods Thirty-two patients underwent at least 2 cycles of chemotherapy A regimen; 30 patients underwent at least 2 cycles of regimen B, that is, thalidomide was administered in combination with regimen A. Results The effective rates of treatment in group A and group B were 84.4% and 86.7%, respectively (P> 0.05). The incidence of adverse reactions of hematologic toxicity in both groups was similar. In non-hematologic toxicities, group B had higher nausea, constipation, motor neuropathy, sensory neuropathy and dizziness than those in group A (P <0.05). Conclusions A-regimen has similar therapeutic effect in treatment of recurrent or refractory MM compared with regimen B and has lower severity of non-hematologic toxicity.